Nicolas Charloteaux - 28 Sep 2020
Worldwide, there are more than 160 initiatives focusing on the development of a COVID-19 vaccine[1]. The majority of these vaccines are still in early stage pre-clinical evaluations. However, currently, at least 42 COVID-19 vaccine candidates are in clinical evaluation[2] – i.e being trialed on healthy volunteers. The World Health Organization (WHO) regularly updates the report on the research & development landscape of COVID-19 candidate vaccines[3].
Vaccines Europe’s member companies are actively contributing to research efforts to develop COVID-19 vaccine candidates. Pharmaceutical companies, biotech firms, academic researchers, public health institutes, governments, regulatory agencies, and NGOs, are joining forces to accelerate vaccine development, share data, knowhow and ideas.
We will need multiple successful vaccines produced at large scale in order to address the need for potentially billions of doses across the world.
For an overview on the latest updates from our members, please visit our webpage.
[1] https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines.
[2] As of September 2020.
[3] https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.
Members area
